The goal of this clinical trial is to evaluate the efficacy of the product in developing immune reinforcement that results in decreased susceptibility to respiratory infections of viral origin in children aged 3 to 10 years with a number of respiratory tract infectious events in the previous year greater than 4. The main questions it aims to answer are: * Has the number of infectious events been reduced from last year? * Does the severity of symptoms decrease with the use of the product? Participants will be treated for 4 months. Treatment efficacy will be evaluated by: * 2 scheduled visits with the investigating pediatrician (T0 - enrollment and start of treatment; T1- end of treatment). * Verification of progress during the study by scheduled telephone meetings. * The use of a diary where the patient or parent/caregiver will report all events (even mild) affecting the respiratory tract, taking care to fully complete the Wisconsin Upper Respiratory Symptom Survey for kids (WURSS-k) questionnaire.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Evaluation of the reduction in the severity of symptoms related to Acute Respiratory Tract Infections
Timeframe: For each infectious event, it should be filled in on the first day of symptoms, on the third day of symptoms, and if symptoms persist, it should also be filled in on the seventh day of symptoms.